Table 5.

Summary of treatment-emergent AEs in Japanese and non-Asian subjects

	Japanese subjects		Non-Asian subjects
	Pooled placebo (n=8)	Pooled verinurad (n=24)	Pooled placebo (n=2)	Pooled verinurad (n=6)
Any AE, n (%) [events]	2 (25.0) [7]	5 (20.8) [5]	0	2 (33.3) [2]
Mild severity	2 (25.0) [7]	4 (16.7) [4]	0	1 (16.7) [1]
Moderate severity	0	1 (4.2) [1]	0	1 (16.7) [1]
Severe severity/life-threatening	0	0	0	0
AE possibly related to study drug, n (%) [events]	1 (12.5) [1]	3 (12.5) [3]	0	1 (16.7) [1]
Mild severity	1 (12.5) [1]	2 (8.3) [2]	0	1 (16.7) [1]
Moderate severity	0	1 (4.2) [1]	0	0
Severe severity/life-threatening	0	0	0	0
Subjects withdrawn due to AEs, n (%) [events]	0	1 (4.2) [1]	0	0
SAEs, n (%) [events]	0	0	0	0

Abbreviations: AEs, adverse events; SAEs, serious adverse events.